Gapping down
In reaction to disappointing earnings/guidance:
- BSFT -4.1%, BRK.B -1.1%, AVXL -1%, NAT -0.5%
M&A news:
- FMS -1.7% (to acquire NXTM for $30/share)
- UTX -1.2% (reports of potential deal with COL)
Other news:
- ZYNE -48.5% (announces top-line results from its Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002g)
- GEMP -31% (announces data based upon its preliminary review of the limited top-line data set from the Phase 2b ROYAL-1 trial)
- CLSN -7.1% (announced that it is taking steps to voluntarily delist the Company's common shares from trading on the Tel Aviv Stock Exchange)
- AMRS -3.1% (files for 42,268,338 share common stock offering by selling stockholders)
- CERS -1.2% (files for $250 mln mixed securities shelf offering)
Analyst comments:
- TEVA -3.5% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- IPI -3.4% (downgraded to Sell from Neutral at UBS)
- BBRY -2.6% (resumed with a Sell at Goldman)
- SABR -1.7% (downgraded to Underperform from Neutral at BofA/Merril)